{"id":671818,"date":"2023-10-11T15:58:01","date_gmt":"2023-10-11T15:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=671818"},"modified":"2023-10-11T15:58:01","modified_gmt":"2023-10-11T15:58:01","slug":"scleroderma-market-set-to-experience-unprecedented-growth-during-the-forecast-period-202332-delveinsight-biocad-kyowa-kirin-bayer-maruho-certa-therapeutics-emerald-health-acceleron","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/scleroderma-market-set-to-experience-unprecedented-growth-during-the-forecast-period-202332-delveinsight-biocad-kyowa-kirin-bayer-maruho-certa-therapeutics-emerald-health-acceleron_671818.html","title":{"rendered":"Scleroderma Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) – DelveInsight | Biocad, Kyowa Kirin, Bayer, Maruho, Certa Therapeutics, Emerald Health, Acceleron"},"content":{"rendered":"
\n
\"Scleroderma<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Scleroderma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Scleroderma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/div>\n

The report covers emerging Scleroderma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Scleroderma treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/em><\/p>\n

Scleroderma: An Overview<\/strong><\/p>\n

Scleroderma is a connective tissue disorder characterized primarily by the thickening and hardening of the skin. The combining form “sclero” means “hard” in Greek, and the word “dermis” means skin. There are two primary types of scleroderma: localized and systemic (also called systemic sclerosis). In localized scleroderma, the disease affects mainly the skin and may have an impact on the muscles and bones. In systemic scleroderma, there is an involvement of the internal organs, such as the digestive tract, heart, lungs, and kidneys, among others. The severity and outcome of scleroderma are variable.<\/p>\n

As scleroderma tends to have many symptoms, a combination approach might often be required for the treatment and management of symptoms in an effective manner. For localized forms of scleroderma, topical medications are often found to be beneficial. Moisturizers can be used for the prevention of the skin from drying out as well as for the treatment of the hardened skin. For improving upon the blood flow, so that the sores within the fingers can heal, nitrates like nitroglycerin are prescribed. The nitrates function by relaxing the smooth muscles, causing dilation of the arteries.<\/p>\n

\"\"<\/p>\n

Scleroderma Market<\/strong><\/a><\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Scleroderma pipeline therapies. It also thoroughly assesses the Scleroderma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.<\/p>\n

The report gives complete details of the market trend for each marketed Scleroderma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.<\/p>\n

Scleroderma Epidemiology Assessment <\/strong><\/p>\n

The epidemiology section provides insights into the historical, current, and forecasted Scleroderma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Scleroderma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. <\/p>\n

Scleroderma Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Scleroderma market or expected to be launched during the study period. The analysis covers the Scleroderma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Scleroderma drugs based on their sale and market share.<\/p>\n

The report also covers the Scleroderma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Scleroderma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n

Learn How the Scleroderma Market Will Evolve and Grow by 2032 @ <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/scleroderma-market<\/strong><\/a><\/p>\n

Scleroderma Therapeutics Analysis<\/strong><\/p>\n

For patients suffering from scleroderma and who have been undergoing worsening pulmonary fibrosis, also called scarring of the lung, the drug cyclophosphamide (Cytoxan), has been found to be useful. For patients dealing with pulmonary hypertension, the most successful form of treatment is the continuous intravenous infusion of epoprostenol (Flolan), a prostaglandin, through a pump. <\/p>\n

Subcutaneous infusion of treprostinil (Remodulin) – a related prostaglandin, is a permitted alternative. Prostaglandins are hormone-like substances that can be found in the body, among various other things, helping in relaxing the smooth muscles and thereby dilating the blood vessels. <\/p>\n

The other forms of therapy that are currently FDA-approved for the treatment of pulmonary hypertension involve oral bosentan (Tracleer), sildenafil (Revatio), and inhaled iloprost (Ventavis).<\/p>\n

Several major pharma and biotech companies are developing therapies for Scleroderma. Currently, Certa Therapeutics<\/strong> is leading the therapeutics market with its Scleroderma drug candidates in the most advanced stage of clinical development.<\/p>\n

Scleroderma Companies Actively Working in the Therapeutics Market Include<\/strong><\/p>\n